Working… Menu

Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00311805
Recruitment Status : Unknown
Verified March 2015 by Losordo, Douglas, M.D..
Recruitment status was:  Active, not recruiting
First Posted : April 6, 2006
Last Update Posted : March 31, 2015
Information provided by (Responsible Party):
Losordo, Douglas, M.D.

Brief Summary:

The goal of the study is to determine the safety and possible effectiveness of various doses of autologous (one's own) stem cells, delivered with a needle into the regions of the leg with poor blood flow in patients with blocked leg arteries that results in claudication (pain when walking). Stem cells are primitive cells produced by the bone marrow that can develop into blood cells or other types of cells. In addition to determining whether this new approach is safe, the diagnostic tests may offer preliminary insights into the usefulness of this approach for treating intermittent claudication - the condition where areas in the leg are lacking enough oxygen and blood flow to keep the leg muscle working well, causing pain and cramping upon walking.

This study is a double-blind, randomized study to compare CD34-positive stem cells versus a placebo agent (salt water solution known as normal saline). The patient will have a 3:1 chance of their stem cells versus the placebo. Regardless of a patient receiving placebo or treatment, all patients will undergo all of the pre-treatment phases of this study, which includes the stem cell mobilization and apheresis procedure.

Condition or disease Intervention/treatment Phase
Peripheral Artery Disease Severe Intermittent Claudication Biological: Autologous Stem Cells (CD34+) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Injection of Autologous CD34-Positive Stem Cells for Neovascularization and Symptom Relief in Patients With Severe Intermittent Claudication
Study Start Date : April 2006
Actual Primary Completion Date : December 2012

Arm Intervention/treatment
Active Comparator: 1 Biological: Autologous Stem Cells (CD34+)
Intramuscular Injections

Active Comparator: 2 Biological: Autologous Stem Cells (CD34+)
Intramuscular Injections

Placebo Comparator: 3 Biological: Autologous Stem Cells (CD34+)
Intramuscular Injections

Primary Outcome Measures :
  1. Safety of Intramuscular administration of CD34-positive cells [ Time Frame: All ]

Secondary Outcome Measures :
  1. Functional improvement [ Time Frame: Week 12, Month 6, Month 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females equal to or greater than 21 years old
  • Patients with infra-inguinal atherosclerosis with a stenosis or occlusion of a major vessel in the affected limb(s) of one or more of the following arteries: superficial femoral, popliteal, or one or more infrapopliteal arteries, which is/are non-reconstructable.
  • Patients with symptoms of Severe Intermittent Claudication in at least 1 lower limb persisting for at least 6 months (Rutherford Class 3).
  • Patients who have a diagnosis of Peripheral Arterial Disease (PAD) in at least 1 lower limb secondary to atherosclerosis, for at least 6 months.

Exclusion Criteria:

  • Patients who have had successful aortic or lower extremity arterial surgery, angioplasty, or lumbar sympathectomy within 3 month preceding screening.
  • Patients with iliac disease amenable to revascularization.
  • Patients judged to be a suitable candidate for surgical or percutaneous revascularization in the limb in which treatment is proposed.
  • Patients with Critical Limb Ischemia (CLI), Rutherford Symptom Score of 4,5, or 6.
  • Patients in who arterial insufficiency in the lower extremity is the result of a non-atherosclerotic disorder.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00311805

Layout table for location information
United States, Alabama
Cardiology, PC
Birmingham, Alabama, United States, 35211
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Losordo, Douglas, M.D.
Layout table for investigator information
Principal Investigator: Douglas W. Losordo, M.D. Northwestern University

Layout table for additonal information
Responsible Party: Losordo, Douglas, M.D. Identifier: NCT00311805     History of Changes
Other Study ID Numbers: STU00023438/STU00000487
11931-01 ( Other Identifier: Sponsor protocol number )
First Posted: April 6, 2006    Key Record Dates
Last Update Posted: March 31, 2015
Last Verified: March 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Intermittent Claudication
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Signs and Symptoms